Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Multiple endocrine neoplasia type 1 (MEN-1) is an autosomal dominant disorder characterized by the combined occurrence of tumours of the parathyroids, pancreatic islet cells and anterior pituitary. Other MEN-1-associated tumours include angiofibromas, collagenomas, lipomas, carcinoids and adrenocortical tumours. The MEN-1 gene, which represents a putative tumour suppressor gene, was identified in 1997, and over 340 mutations have been reported in MEN-1 families, patients with non-familial MEN-1, families with isolated primary hyperparathyroidism and those with sporadic non-MEN-1 endocrine tumours. The mutations are scattered throughout the nine exons that encode a 610 amino acid nuclear protein (MENIN), which interacts with the transcriptional factor JunD. These recent developments have made it possible to consider genetic screening for this inherited disorder.

Original publication




Journal article


Best Practice and Research: Clinical Endocrinology and Metabolism

Publication Date





189 - 212